Articles tagged with Dna Repair Genes
Researchers discovered a small molecule, UNI418, that destabilizes key DNA repair proteins, making drug-resistant cancer cells vulnerable to PARP inhibitor therapy. This approach restores tumor sensitivity and improves treatment outcomes.
Researchers have captured the most detailed structural images to date of a specific type of protein's DNA repair process, revealing key steps in its repair activities. The findings provide insights for drug targets that could halt the process in cancer cells empowered by mutated BRCA genes.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.
Researchers discovered that Nup98 forms droplet-like structures to protect broken DNA in tightly packed zones, allowing for accurate repairs and reducing genetic mistakes. This finding has implications for cancer and aging, with potential applications for therapies that mimic Nup98's protective functions.
A protein complex has been identified that repairs abnormal DNA responsible for neurodegenerative disease Huntington's. This discovery could lead to the development of a therapeutic target to delay or prevent disease onset.
A new study published in Aging-US has identified the p53-p16/RB-E2F-DREAM complex as a critical regulator of cellular senescence. The researchers found that this complex represses multiple target genes involved in cell cycle regulation, DNA repair, and chromatin structure, leading to the stability of the senescent arrest.
Scientists discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. DNA polymerase θ (POLQ) is an important factor in repairing complex DNA double-strand breaks, and inhibiting POLQ may augment the efficacy of heavy ion radiation therapy.
A new study led by Tokyo University of Science researchers identifies altered gene expression and cell function changes that drive DNA damage and neoplasia in cholangiocytes exposed to 1,2-dichloropropane. The findings highlight the importance of macrophage involvement in carcinogenesis.
Researchers at the University of Birmingham have discovered two new DNA repair genes, SETD1A and BOD1L, which can make cancer cells more sensitive to radiotherapy. These findings may lead to improved treatment efficiency and patient outcomes by allowing clinicians to identify targeted treatments for specific patients.
An international team of engineers has successfully bioprinted bone along with two growth factor encoding genes that help incorporate cells and heal defects in rats. The researchers used gene encoding PDGF-B and BMP-2, which encouraged cell multiplication and migration, resulting in a 40% increase in bone tissue creation.
A marine-dwelling creature, Trichoplax adhaerens, has been found to resist cancer and repair DNA after radiation damage. Researchers are exploring its unique properties to develop new therapies for cancer.
A study found that men with Li-Fraumeni syndrome have a 25-fold increased risk of developing aggressive prostate cancer, and those with inherited TP53 variants are diagnosed at a young age. Routine screening for prostate cancer is recommended for these individuals.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
The study describes the three-dimensional structure of the MUTYH protein and its interaction with PCNA, a key player in DNA replication. The researchers found that mutations in the MUTYH gene reduce its binding affinity to DNA and destabilize its structure, leading to decreased DNA repair activity.
Researchers analyzed DNA data from African American and Caucasian American men with prostate cancer, finding lower frequencies of pathogenic/likely alterations in 14 well-characterized DNA repair genes among African Americans. The study suggests a higher risk for germline BRCA mutations but lower risks for non-BRCA mutations
A new study found that sleep deprivation can cause DNA damage in healthy individuals, increasing the risk for cancer, cardiovascular, metabolic, and neurodegenerative diseases. Even a single night of sleep deprivation can trigger events contributing to chronic disease development.
A study found that over 10% of men with metastatic prostate cancer have inherited mutations in DNA repair genes, more than four times the general population rate. These mutations could benefit from targeted treatment already approved for ovarian cancer patients.
An international team of researchers has established the cause of rare Fanconi Anemia: a de novo mutation in the RAD51 gene. The mutation leads to chromosome instability, bone marrow failure, leukemia, and solid tumors, resulting in a significantly reduced life expectancy.
A study found that genetic variations in DNA repair genes can affect a person's risk of developing Hodgkin disease. Research suggests that differences in these genes could modify the risk of HD, with some individuals being up to four times more likely to develop the disease.
A comprehensive review of 241 gene variants and cancer risk identified only two statistically significant associations, including an XRCC1 allele and ERCC2 allele linked to lung cancer. The findings suggest that genetic risks are typically modest, and large-scale evidence is needed to establish specific associations.
A recent study published in the International Journal of Cancer found a link between arsenic exposure and suppressed expression of DNA repair genes. The researchers discovered that individuals with elevated arsenic levels had lower levels of certain genes involved in nucleotide excision repair, which helps protect against DNA damage.
Researchers discovered that the Rad54 gene plays a vital role in repairing DNA breaks in a neat and efficient manner, preventing mutations. The study's findings suggest that individuals without this gene may be more susceptible to radiation therapy side effects and could benefit from milder treatment protocols.
Scientists have identified a key gene, Rad54, involved in neat DNA repair, preventing mutations and potentially improving cancer treatment. The study found that patients with an inactive Rad54 gene are more susceptible to radiotherapy side effects, leading to the idea of milder treatments.